Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market
February 28, 2020 08:45 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 28, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS, INC. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a...
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)
February 26, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today a strategic...
Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering
February 11, 2020 16:01 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the closing of its...
Tonix Pharmaceuticals Prices $7.5 million Public Offering
February 07, 2020 08:45 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an...
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD
February 05, 2020 17:15 ET
|
Tonix Pharmaceuticals Holding Corp.
RECOVERY Study has Stopped Enrollment Due to Inadequate Separation from Placebo at Week-12 Based on Interim Analysis Results of the First 50% of Enrolled Participants Company Plans to Unblind and...
Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences
February 04, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate in three upcoming...
Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
January 29, 2020 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, presented preclinical results of...
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL
January 24, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tonix Expects the Data to Satisfy Pharmacokinetic Requirements for Potential New Drug Applications for TNX-102 SL for PTSD and Fibromyalgia Lack of a Food Effect for TNX-102 SL Supports...
Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
January 23, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will be...
Tonix Pharmaceuticals to Present at Biotech Showcase 2020
January 07, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer...